GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

About this update from Genedx Holdings Corp.

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx’s industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diagnoses faster and guide clinical decision-making. De-identified data from the program will be added to GeneDx Infinity™, the largest and most comprehensive rare disease dataset, to help drive faster diagnoses of NPC to help patients and providers make informed treatment decisions. NPC is a rare, inherited, and often underdiagnosed condition that can progress relentlessly while families search for answers. Through this program, eligible patients in the United States will have access to genomic testing via GeneDx to help confirm or rule out a diagnosis of NPC. Providing data to support an accurate diagnosis is a critical step in guiding patient management and identifying individuals who may benefit from available therapies. The program builds on Zevra’s leadership in NPC underscoring the growing importance of timely and accurate genetic diagnosis as new treatment options emerge. “When a disease is progressive and treatable, every day matters. Through our partnership with Zevra we are removing barriers to high-quality exome sequencing so clinicians can reach answers faster, confirm diagnoses with precision, and identify patients earlier,” said Lisa Gurry, Chief Business Officer at GeneDx. “Our partnership programs are fueled by the GeneDx Infinity™ dataset – the world’s largest rare-disease genomic dataset – enabling biopharma partners to better understand disease biology, and accelerate the patient journey from diagnosis to treatment. This is how we translate genomic insight into transformative, real-world impact for patients.” NPC is caused by mutations in the NPC1 and NPC2 genes that impair the body’s ability to transport cholesterol ...

View stock analysis, news, and events for Genedx Holdings Corp.